NMRA Stock Forecast & Price Target

Neumora Therapeutics Inc. is positioned for significant growth, with projected U.S. sales reaching $250 million by 2030 and soaring to $950 million by 2035, in alignment with consensus expectations. The company's diverse pipeline, which includes seven clinical and preclinical programs targeting novel mechanisms for neuropsychiatric and neurodegenerative conditions, showcases its commitment to addressing underserved markets, particularly highlighted by the promising developments surrounding NMRA-511 and its improved efficacy profile in Alzheimer's disease agitation. Furthermore, the potential of Navacaprant as a differentiated treatment option in major depressive disorder, with an estimated U.S. sales potential of $750 million in 2028 and a peak estimate of $3 billion, reinforces a strong and favorable outlook for the company's financial trajectory.

Neumora Therapeutics Inc. reported a significant net loss of $59.5 million in the fourth quarter of 2025, indicating financial strain as research and development expenses reached $44.7 million, necessitating continuous fundraising efforts until the company achieves cash flow positivity. Concerns surrounding adverse events from the NMRA-215 toxicity study have raised investor apprehension, leading to a notable decline in stock value and creating an overhang on the program's potential. Additionally, the higher screen failure rates of approximately 71% and unexpected safety issues across various trials contribute to the increasing risk profile, exacerbating uncertainties surrounding the company's future prospects.